Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
OGEN - Oragenics Inc.
Market Cap 7.37M P/E - EPS this Y - Ern Qtrly Grth -
Income -19.52M Forward P/E -0.34 EPS next Y - 50D Avg Chg 8.00%
Sales 7.47k PEG - EPS past 5Y - 200D Avg Chg -41.00%
Dividend N/A Price/Book 0.85 EPS next 5Y - 52W High Chg -85.00%
Recommedations 2.00 Quick Ratio 0.98 Shares Outstanding 8.66M 52W Low Chg 40.00%
Insider Own 12.02% ROA -219.89% Shares Float 4.72M Beta 0.48
Inst Own 14.01% ROE -454.72% Shares Shorted/Prior 174.44K/701.41K Price 3.64
Gross Margin - Profit Margin - Avg. Volume 11,241 Target Price -
Oper. Margin -263,285.18% Earnings Date Nov 7 Volume 8,775 Change -3.70%
Healthcare | Biotechnology | United States
About Oragenics Inc.

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Oragenics Inc. News
12/16/24 Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
10/18/24 Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
10/09/24 Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
10/08/24 Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
10/08/24 EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate
09/05/24 Oragenics, Inc. Announces Closing of Public Offering
09/04/24 Oragenics, Inc. Announces Pricing of Public Offering
08/21/24 Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
08/16/24 Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
08/14/24 Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
08/12/24 Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
08/09/24 Oragenics: Q2 Earnings Snapshot
08/08/24 Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
08/08/24 EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway
07/10/24 Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
06/27/24 Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
06/24/24 Oragenics, Inc. Announces Proposed Public Offering
06/20/24 Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
05/22/24 Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
05/17/24 Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Telling Fred Director Director Nov 30 Sell 3.5681 3,500 12,488 38,345 12/01/23
Telling Fred Director Director Jun 17 Buy .2860 10,084 2,884 1,010,000 06/21/22
Sullivan Michael O'Keefe Interim PEO, CFO Interim PEO, CFO Mar 29 Buy .3461 20,000 6,922 34,255 03/30/22